NRG And TerThera Cooperate To Secure Terbium-161 Supply Last week, NRG (ENS Corporate Member) and TerThera signed an agreement for irradiation services in the High Flux Reactor in Petten to produce Terbium-161. The non-carrier-added (NCA) Terbium-161 is produced by neutron irradiation of highly enriched Gadolinium-160 targets in the Dutch research reactor. Terbium-161 is a promising novel…
“Nuclear medicine has a great unexplored potential” Interview with Anthony Waked, PhD Fellow at SCK CEN – Belgian Nuclear Research Centre and the University of Liège, Belgium In the past decade, research has made tremendous progress and medical isotopes are expected to become a vital tool in the treatment of many types of cancers in…
SCK CEN Announced A New Partnership To Accelerate The Fight Against Cancer The Belgian Nuclear Research Centre SCK CEN (ENS Corporate Member) announced that the US-based SpectronRx will open its first European radiolabeling facility for sorely needed medical radioisotopes. The facility will be established on the premises of the research centre in Mol, Belgium. Both…
SCK CEN And TerThera Collaborate To Secure Terbium-161 Supply SCK CEN (ENS Corporate Member) and TerThera signed an agreement to handle together the production process of Terbium-161, a promising novel radionuclide for cancer treatment. Terbium-161 can meet the growing demand in cancer healthcare, exhibiting comparable (radio)chemical characteristics to known radiolanthanides. Targeted cancer therapies with Terbium-161 are expected…
MARIA Research Reactor To Be Modernised By 2027 On 20th June 2023, the Council of Ministers of Poland adopted a resolution on the MARIA nuclear research reactor modernisation programme, so as to enable its operation beyond 2027. The MARIA reactor is currently the only and unique research facility of this type in Poland and in…
PSI Leads New Research To Fight Metastatic Prostate Cancer Researchers at the Paul Scherrer Institute (ENS Corporate Member, PSI) are developing a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug, studied by a research consortium involving PSI, the University Hospital Basel and ETH Zurich, is now being…
PSI Pioneers Proton Radiotherapy To Treat A Rare Type of Cancer Paul Scherrer Institute (PSI, ENS Corporate Member) and the University Hospital Zurich treated for the first time in Switzerland a patient affected by an oesophageal tumour by using proton radiotherapy. This research is part of the pan-European PROTECT trial (PROton versus photon Therapy for…
Full Financing For PALLAS Reactor Announced By Dutch Minister The Dutch Minister of Health, Welfare and Sport Ernst Kuipers announced yesterday that there is full financing for the construction of the PALLAS reactor. This is a major step towards realising the new facility in Petten, North Holland. The construction of a new reactor would be…
ENS at the 67th IAEA General Conference ENS seat at the IAEA GC Plenary Session From 25th to 29th September, Vienna hosts the 67th General Conference of the International Atomic Energy Agency (IAEA). More than 2,800 participants from Member State delegations, international organisations, and NGOs registered to attend the 4-days event at the IAEA headquarter.…
NRG|PALLAS Started The First Irradiation Cycle Of 2024 For Lutetium Last week, NRG|PALLAS (ENS Corporate Member) announced the launch of the first cycle of irradiation of the year focusing on lutetium for medical applications. The Dutch company, operating the High Flux Reactor in Petten (The Netherlands), said the cycle started on 19 January, with the…